Summary:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin In Subjects With Compensated Cirrhosis or Fibrosis Due To Nonalcoholic Steatohepatitis (Nash)/Metabolic Dysfunction-Associated
Steatohepatitis (Mash)
Qualified Participants Must:
• 18-80 years old male or female
•
BMI over 25
•
Diagnosis of Fibrosis or Cirrhosis